New anti hepatitis C drugs are on the market in China, interferon has become the future

In April last year, the drug evaluation center (CDE) of the State Food and Drug Administration announced that 10 new anti hepatitis C drugs from 7 enterprises were included in the priority evaluation procedure, and the registration application of new anti hepatitis C drugs has entered the fast lane since then A year later, the approval of new hepatitis C drugs officially kicked off the market, and new hepatitis C direct antiviral drugs such as ashuribe, dalatavir, simiravei, sofibuprovir and obipali entered the country one after another through green channels Up to now, six new antiviral drugs for hepatitis C from four enterprises have passed the priority review and have been listed in China On April 24, 2017, Bristol Myers Squibb's dalatavir hydrochloride and ashuribe soft capsules were first approved; then on August 28, Johnson & Johnson's simirave capsule also passed the approval; on September 21, Gilead and eberver's new oral drugs for hepatitis C, suofebuvir tablets In addition, elbasvir + grazoprevir of mosadong and danorevir of Geli are under review The launch of a series of new anti HCV drugs has opened a new chapter in the history of anti HCV drugs in China
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> on December 10, 2013, the European Society of Hepatology released the guideline for diagnosis and treatment of hepatitis C virus (HCV) infection Subsequently, on April 9, 2014, the World Health Organization issued the guidelines for the treatment of hepatitis C This is a leap from quantitative change to qualitative change in the global chemical treatment of hepatitis C under the situation of new drugs emerging in large numbers, promoting the treatment of hepatitis C has entered a new era From 2011 to August 2017, the US FDA approved the listing of 10 new oral anti HCV drugs, completely subverting the anti HCV treatment market Especially after sofosbuvir (sofafrevir) came out, sofafbuvir / redipavir, obipali + palirave + litonavir + dasebovir, dalatavir + ashurevir, ibaasvir + gezopravir, sofafbuvir / vepatavir, and glecaprevir + pibrentasvir and other cocktail therapies came out one after another, bringing hope for the survival of hepatitis C patients and promoting the market of hepatitis C treatment Reshuffle
According to the annual financial report of multinational pharmaceutical companies, the global anti HCV drug market reached a peak of US $24.757 billion in 2015, an increase of 41.26% over the previous year; with the competitive listing of new anti HCV drugs, the emerging market of Gilead sovaldi in the United States changed and the market entered into normalization; the global anti HCV drug market in 2016 was US $18.721 billion, an increase of 41.26% over the previous year The annual decline was 24.29%
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> interferon status is not the same as before Interferon and ribavirin were the first-line drugs for the treatment of hepatitis C, especially pegylated interferon α - 2A and PEGylated interferon α - 2b were used as the engine of anti hepatitis C market after they were listed With the advent of oral drugs for anti HCV treatment, anti HCV interferon has been hit hard, which also led to the overall market decline of interferon In 2016, the global interferon market dropped from a high of US $9.5 billion in 2012 to US $5.4 billion, a year-on-year drop of 26.68% in 2016 Oral direct acting antiviral drugs (DAAS) have high safety and effectiveness, which have brought huge impact on interferon drugs Interferon products will play a role in multiple sclerosis and hepatitis B treatment platforms According to the analysis of epidemiological experts, there are about 10 million hepatitis C patients in China As hepatitis C is highly secretive and most patients lack of understanding of the disease, early detection, diagnosis and treatment of hepatitis C are difficult to achieve at present In China, hepatitis C patients have been in the late stage of the disease at the time of discovery and missed the best period of disease treatment, so it is very important to control hepatitis C, improve the understanding of hepatitis C, early diagnosis and adhere to treatment The combination of interferon and ribavirin is the main treatment plan; the main drugs used in chronic hepatitis C are pegylated interferon α - 2A, recombinant human interferon α - 2b, pegylated interferon α - 2b, recombinant human interferon α - 1B and ribavirin Although peg-INF / ribavirin therapy has become the gold standard of hepatitis C treatment in China, its cure rate is 44% - 70% In terms of treatment, at present, only less than 2% of patients diagnosed as hepatitis C use interferon based antiviral treatment; and the later hepatitis C is treated, the more complications, the higher the cost of treatment Hepatitis C has brought a heavy economic burden to the families and countries of the patients and has become a serious social problem According to the data of minenet, the sales volume of interferon in public hospitals in key cities in 2016 was 483 million yuan, down 21.46% year on year Interferon will continue to decline with the new oral anti HCV drugs on the market in China With the progress of human science, today's new drug research and development has been different from the past, and we are facing the challenge of new targets; yesterday's scenery is infinite, tomorrow's may be moribund
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the development of domestic anti hepatitis C suofebuvir is in full swing According to the data on CFDA official website, 20 treatment numbers of suofebuvir bulk drug and oral tablets have been published in China, and there are 2 acceptance numbers of radypavesuofebuvir tablets Zhengda Tianqing Pharmaceutical Co., Ltd., Sichuan Kelun, Fujian Haixi new drug development Co., Ltd., Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd., Zhejiang Haizheng Pharmaceutical Co., Ltd., Zhongqi Pharmaceutical Group, Jiangxi Shimei Pharmaceutical Co., Ltd., Beijing Wansheng Pharmaceutical Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd and other enterprises are pushing ahead with great efforts The total investment in R & D has exceeded 50 million yuan In March 2017, suofebuvir of Shanghai Hequan Pharmaceutical Co., Ltd was approved for clinical application (cyhl1600001 Zhejiang), and suofebuvir patavir tablets (cxhl1600141 Zhejiang) of geelia (Hangzhou) pharmaceutical were also in progress With the coming into the market of domestic new oral anti HCV drugs, the short board of chronic hepatitis C drug treatment will be alleviated
none="shifuMouseDownCard('shifu_c_029')" label="Copyright Reserved by PLAYHUDONG." style="margin: 1em 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: 0px; box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> how to choose the best treatment plan when there are so many new hepatitis C drugs linked? You can refer to the following four dimensions of comparative analysis
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> dimension one: there are many subtypes of hepatitis C in different genotypes, and the main genotype in China is 1b, accounting for 56.8% of the total Because the optimal treatment plan of different genotypes is different, it is necessary to detect the virus genotypes of patients before taking oral antiviral drugs Currently, DAA drugs approved for marketing in China or included in the priority review mostly cover genotype 1, and some need to be used in combination with ribavirin or other drugs
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> dimension two: the cure rate and treatment course of different new hepatitis C drugs From the current exposure of several new hepatitis C drugs, the treatment cycle varies from 12 weeks to 24 weeks, and svr12 also has some differences
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> dimension three: baseline drug resistance affects drug selection physicians Before enabling some DAA schemes, they need to test whether patients have baseline drug resistance, and then decide which treatment scheme to choose
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> dimension four: DAA combination drugs of different treatment schemes mainly include NS3 / 4A protease inhibitor, NS5A protein inhibitor, NS5B polymerase inhibitor, etc different new hepatitis C drugs have different DAA combinations
1  China’s HBV and HCV Prevention Guideline, P906 guidelines for the prevention and treatment of chronic hepatitis B and hepatitis C in China, page 906, 2 the first all oral direct anti hepatitis C combined treatment program - BLZ ® and swipe ® approved in China http://news.medlive.cn/liver/info-progress/show-127104_.html 3 Ibove's treatment plan of weijianle ® (obipali tablets) combined with yichiri ® (dacebuvir sodium tablets) was approved in China for the treatment of gene 1 chronic hepatitis C http://news.bioon.com/article/6710437.html? From = single message & isappinstalled = 0 4 new anti hepatitis C drugs in Hangzhou